Compare SPFI & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPFI | CRVS |
|---|---|---|
| Founded | 1941 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 820.1M | 811.8M |
| IPO Year | 2019 | 2016 |
| Metric | SPFI | CRVS |
|---|---|---|
| Price | $43.68 | $10.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $50.50 | $33.14 |
| AVG Volume (30 Days) | 80.1K | ★ 1.0M |
| Earning Date | 10-22-2026 | 11-03-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | 17.81 | ★ 48.04 |
| EPS | ★ 1.82 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.77 | N/A |
| Revenue Next Year | $8.74 | N/A |
| P/E Ratio | $24.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.34 | $6.39 |
| 52 Week High | $46.94 | $26.95 |
| Indicator | SPFI | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 51.33 | 39.79 |
| Support Level | $42.76 | $9.21 |
| Resistance Level | $44.13 | $13.73 |
| Average True Range (ATR) | 0.85 | 0.56 |
| MACD | 0.16 | 0.07 |
| Stochastic Oscillator | 61.31 | 50.65 |
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking. The majority of the company's revenues is derived from interest income and other sources, including loans, securities and derivatives.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.